Jan 30, 2020: The coronavirus outbreak is having a potentially considerable social and economic impact in China.4
WuXi Biologics is directly monitoring the coronavirus outbreak and is complying with guidance from the relevant authorities.
Overall, less than 6% of staff have travelled to Wuhan, transited through Wuhan or had contact with people coming from Wuhan. No employee has been diagnosed with the infection.
We are closely monitoring the health of every employee. We have a sufficient number of staff to resume operations after the holiday break.
WuXi Biologics is also working carefully to ensure the quality of the products we are manufacturing is not affected by this outbreak. They have a strong GMP quality system and a robust global supply chain and not expect to see any negative impact of this outbreak on our operations.
Clients who plan to travel to China are suggested to conduct meetings via videoconferences or teleconferences. In addition, WuXi Biologics has already mobilized a large team in order to develop and manufacture multiple neutralizing antibodies to potentially treat the infection.
WuXi Vaccines, an additional of WuXi Biologics dedicated to vaccines, is also in discussion on the manufacturing of multiple novel vaccines. https://www.wuxibiologics.com/wuxi-biologics-provides-operation-update-related-coronavirus-outbreak/
